Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies

Next Previous
Trial Profile

An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pamiparib (Primary) ; Tislelizumab (Primary) ; Bevacizumab; Capecitabine; Fruquintinib; Ociperlimab; Pemetrexed; Sitravatinib; Temozolomide
  • Indications Cancer; Glioblastoma; Solid tumours
  • Focus Adverse reactions; Registrational
  • Sponsors BeOne Medicines

Most Recent Events

  • 27 Mar 2026 Status changed from recruiting to active, no longer recruiting.
  • 16 Mar 2026 Planned End Date changed from 1 Dec 2026 to 1 Jul 2026.
  • 16 Mar 2026 Planned primary completion date changed from 1 Dec 2026 to 1 Jul 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top